Claims
- 1. A composition for method of making sequence variants in vitro from at least one heteroduplex polynucleotide where said heteroduplex has at least two non-complementary nucleotide base pairs, said composition comprises an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity.
- 2. An in vitro method of making sequence variants from at least one heteroduplex polynucleotide wherein said heteroduplex has at least two non-complementary nucleotide base pairs, said method comprising:
a. preparing at least one heteroduplex polynucleotide; b. combining said heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity; and c. allowing sufficient time for the percentage of complementarity to increase, wherein at least one or more variants are made.
- 3. The method of claim 2 wherein said heteroduplex polynucleotide is circular.
- 4. The method of claim 2 wherein said heteroduplex polynucleotide is linear.
- 5. The method of claim 3 or 4 wherein said heteroduplex polynucleotide is a replicon.
- 6. The method of claim 2 wherein said variants have different amounts of complementarity.
- 7. The method of claim 2 wherein said agents having strand cleavage activity, exonuclease activity and polymerase activity are added sequentially.
- 8. The method of claim 2 wherein said agents having exonuclease activity, polymerase activity, and strand cleavage activity are added concurrently.
- 9. The method of claim 2 in step (b) further comprising ligase activity.
- 10. The method of claim 2 further comprising a step of,
(d) adding a ligase.
- 11. The method of claim 9 wherein said agents having strand cleavage activity, exonuclease activity, polymerase activity and ligase activity are added sequentially.
- 12. The method of claim 9 wherein said agents having exonuclease activity, polymerase activity, ligase activity, and strand cleavage activity are added concurrently.
- 13. The method of claim 9 wherein said ligase is T4 DNA ligase, E. coli DNA ligase, or Taq DNA ligase.
- 14. The method of claim 2 wherein said agent with strand cleavage activity is an enzyme.
- 15. The method of claim 2 wherein said agent with strand cleavage activity is a mismatch endonuclease.
- 16. The method of claim 2 wherein said agent with strand cleavage activity is selected from the group consisting of CEL I, T4 endonuclease VII, T7 endonuclease i, S1 nuclease, BAL-31 nuclease, FEN1, cleavase, pancreatic DNase I, SP nuclease, mung bean nuclease, and nuclease P1.
- 17. The method of claim 2 wherein said agent with strand cleavage activity is a chemical.
- 18. The method of claim 2 wherein said agent with strand cleavage activity is selected from the group consisting of potassium permanganate, tetraethylammonium acetate, sterically bulky photoactivatable DNA intercalators, [Rh(bpy)2(chrysi)]3+, osmium tetroxide with piperidine, and hydroxylamine with piperidine.
- 19. The method of claim 2 wherein said agent with strand cleavage activity is ionizing radiation, or kinetic radiation.
- 20. The method of claim 2 wherein said agent with polymerase activity is T4 DNA polymerase.
- 21. The method of claim 2 wherein said agent with polymerase activity is T7 DNA polymerase.
- 22. The method of claim 2 wherein said agent with polymerase activity and also has exonuclease activity is T4 DNA polymerase, T7 DNA polymerase, E. coli Pol I, or Pfu DNA polymerase.
- 23. The method of claim 22 wherein said agent is E. coli Pol I.
- 24. The method of claim 2 wherein said effective amount of strand cleavage activity, and exonuclease activity/polymerase activity and ligase activity are provided by CEL I, T4 DNA polymerase, and T4 DNA ligase.
- 25. The method of claim 2 wherein said effective amount of strand cleavage activity, and exonuclease activity/polymerase activity and ligase activity are provided by CEL I, T7 DNA polymerase, and T4 DNA ligase.
- 26. The method of claim 2 wherein an effective amount of strand cleavage activity, and exonuclease activity/polymerase activity and ligase activity are provided by T4 endonuclease VII, T4 DNA polymerase, and T4 DNA ligase.
- 27. An in vitro method of increasing diversity in a population of sequences, comprising: preparing at least one heteroduplex polynucleotide; combining said heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity; and allowing sufficient time for the percentage of complementarity to increase, wherein diversity in the population is increased.
- 28. The method of claim 27 wherein said heteroduplex polynucleotide is circular.
- 29. The method of claim 27 wherein said heteroduplex polynucleotide is linear.
- 30. The method of claim 3 or 4 wherein said heteroduplex polynucleotide is a replicon.
- 31. The method of claim 27 wherein said variants have different amounts of complementarity.
- 32. The method of claim 27 wherein said enzymes having and strand cleavage activity, 3′ to 5′ exonuclease activity and polymerase activity are added sequentially.
- 33. The method of claim 27 wherein said enzymes having 3′ to 5′ exonuclease activity, polymerase activity, and strand cleavage activity are added at the same time.
- 34. The method of claim 27 further comprising adding a ligase.
- 35. The method of claim 9 wherein said ligase is T4 DNA ligase, E. coli DNA ligase, or Taq DNA ligase.
- 36. The method of claim 27 wherein said agent with strand cleavage activity is an enzyme.
- 37. The method of claim 27 wherein said agent with strand cleavage activity is a mismatch endonuclease.
- 38. The method of claim 27 wherein said agent with strand cleavage activity is selected from the group consisting of CEL I, T4 endonuclease VII, T7 endonuclease i, S1 nuclease, BAL-31 nuclease, FEN1, cleavase, pancreatic DNase I, SP nuclease, mung bean nuclease, nuclease P1.
- 39. The method of claim 27 wherein said agent with strand cleavage activity is a chemical.
- 40. The method of claim 27 wherein said agent with strand cleavage activity is selected from the group consisting of potassium permanganate, tetraethylammonium acetate, sterically bulky photoactivatable DNA intercalators, [Rh(bpy)2(chrysi)]3+, osmium tetroxide with piperidine, and hydroxylamine with piperidine.
- 41. The method of claim 27 wherein said agent with strand cleavage activity is ionizing radiation, or kinetic radiation.
- 42. The method of claim 27 wherein said agent with polymerase activity is T4 DNA polymerase.
- 43. The method of claim 27 wherein said agent with polymerase activity is T7 DNA polymerase.
- 44. The method of claim 27 wherein said agent with both polymerase activity and 3′ to 5′ exonuclease activity is T4 DNA polymerase, T7 DNA polymerase, E. coli Pol 1, or Pfu DNA polymerase.
- 45. The method of claim 27 wherein said agent with both polymerase activity and 5′ to 3′ exonuclease activity is E. coli Pol 1.
- 46. The method of claim 27 wherein said effective amount of strand cleavage activity, exonuclease activity/polymerase activity and ligase activity are provided by CEL I, T4 DNA polymerase, and T4 DNA ligase respectively.
- 47. The method of claim 27 wherein said effective amount of strand cleavage activity, and exonuclease activity/polymerase activity and ligase activity are provided by CEL I, T7 DNA polymerase, and T4 DNA ligase respectively.
- 48. The method of claim 27 wherein said effective amount of strand cleavage activity, and exonuclease activity/polymerase activity and ligase activity are provided by CEL I, T7 DNA polymerase, and T4 DNA ligase respectively.
- 49. The method of claim 27 wherein an effective amount of strand cleavage activity, and exonuclease activity/polymerase activity and ligase activity are provided by T4 endonuclease VII, T4 DNA polymerase, and T4 DNA ligase respectively.
- 50. A composition for increasing diversity in vitro in a population of sequences in the form of one or more heteroduplexes where each heteroduplex has at least two non-complementary nucleotide base pairs, said composition comprises an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity.
- 51. A method of obtaining a polynucleotide encoding a desired functional property, comprising:
a. preparing at least one heteroduplex polynucleotide; b. combining said heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity, and strand cleavage activity; c. allowing sufficient time for the percentage of complementarity between strands of the heteroduplex polynucleotide to increase, wherein diversity in the population is increased; and d. screening or selecting a population of variants for the desired functional property.
- 52. The method of claim 51 further comprising:
converting DNA to RNA after diversity in the population has been increased; and wherein the population of variants being screened or selected are ribonucleic acid variants for the desired functional property.
- 53. The method of claim 52 further comprising:
translating said RNA into a polypeptide; and wherein the population of variants being screened or sel3ected are polypeptide variants for desired functional property.
- 54. A method of obtaining a polynucleotide encoding a desired functional property, comprising:
a. preparing at least one heteroduplex polynucleotide; b. combining said heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity; c. allowing sufficient time for the percentage of complementarity between strands of said heteroduplex polynucleotide to increase, d. denaturing said population of variants to obtain single strand polynucleotides; e. annealing said single strand polynucleotides to each other or to a parent single stranded polynucleotide to form at least one second heteroduplex polynucleotide; f. combining said second heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity; and g. allowing sufficient time for the percentage of complementarity between strands of the heteroduplex polynucleotide to increase.
- 55. The method of claim 54 wherein said heteroduplex polynucleotide is greater than 95% identical.
- 56. The method of claim 54 wherein said heteroduplex polynucleotide is about 95% identical.
- 57. The method of claim 54 wherein said heteroduplex polynucleotide is about 90% identical.
- 58. The method of claim 54 wherein said heteroduplex polynucleotide is about 85% identical.
- 59. The method of claim 54 wherein said heteroduplex polynucleotide is about 80% identical.
- 60. The method of claim 54 wherein said heteroduplex polynucleotide is about 75% identical.
- 61. The method of claim 2 wherein the heteroduplex polynucleotide is about 1000 Kb.
- 62. The method of claim 2 wherein the heteroduplex polynucleotide is about 10,000 Kb.
- 63. The method of claim 2 wherein the heteroduplex polynucleotide is about 100,000 Kb.
- 64. The method of claim 54 further comprising;
screening or selecting for a population of fariants having a desired functional property after step c. or after step g.
- 65. A kit used for increasing diversity in a population of sequences by a method comprising, preparing at least one heteroduplex polynucleotide; combining said heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity; and allowing sufficient time for the percentage of complementarity to increase, wherein diversity in the population is increased;
wherein said kit comprises a plurality of vessels containing an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity.
- 66. The kit of claim 65 further comprising an agent or agents having a ligase activity.
- 67. A nicked plasmid heteroduplex which has at least two non-complementary nucleotide base pairs and a nick located at at least one of the two non-complementary nucleotide base pairs.
- 68. The nicked plasmid heteroduplex of claim 67 wherein a nick is located at both of the two non-complementary nucleotide base pairs.
- 69. A method for altering the length of a polynucleic acid sequences resolved within a heteroduplex comprising;
a. preparing at least one heteroduplex polynucleotide; b. combining said heteroduplex polynucleotide with an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity; and c. allowing sufficient time for the percentage of complementarity between strands of said heteroduplex polynucleotide to increase, wherein the ratio of polymerase activity to ligase activity is altered to obtain a desired length of resolution between the polynucleotide strands of the heteroduplex.
- 70. A method of generating mutations in a zone around a particular nucleotide within a desired polynucleotide comprising;
a. preparing at least one partially complementary polynucleotide having at least one non-complementary nucleotide within the corresponding zone of the desired polynucleotide, b. forming at least one heteroduplex between said desired polynucleotide and said partially complementary polynucleotide; c. combining said heteroduplex with an at least one nucleotide analogue, effective amount of an agent or agents with exonuclease activity, polymerase activity, and strand cleavage activity; and d. allowing sufficient time for the nucleotide analogue to be incorporated into either said desired polynucleotide, said partially complementry polynucleotide or both.
- 71. The method according to claim 70 further comprising having a ligase activity.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of the filing date of U.S. Provisional Application No. 60/402,342 filed Aug. 8, 2002 and is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60402342 |
Aug 2002 |
US |